IMMUNEERING CORP - CLASS A
IMRXNASDAQ๐ #3487 by market capEarnings Nov 11US Equity
$4.13โผ $0.03 (โ0.72%)
๐ After hours$4.07โผ 1.45%Regular close ยท extended-hours price shownTrack IMRX
Get earnings, price moves & breaking news on Telegram
24hโผ 0.7%
7dโผ 5.9%
14dโผ 7.4%
30dโผ 17.2%
ytdโผ 37.1%
1yโผ 40.8%
๐ฆMarket Cap
$267M
Small Cap
๐Revenue Growth (YoY)
โ
๐Gross Margin
28.0%
Moderate
๐ตFCF Margin
โ
โ๏ธP/S Ratio
534.4x
Expensive
Otter Score
60
Fair
IMMUNEERING CORP - CLASS A
IMRXAnalyst Ratings
Price
$4.13
Total
11
Raised
0
Lowered
3
Avg PT
$15.50
H / L
$17 / $14
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
Needham | Reiterated | Buy | 2026-07-20 | โ | โ |
Chardan Capital | Reiterated | Buy | 2026-05-19 | โ | โ |
HC Wainwright & Co. | Reiterated | Buy | 2025-09-30 | โ | โ |
Oppenheimer | Reiterated | Outperform | 2025-09-25 | $30.00 | +626.40% |
Mizuho | Reiterated | Outperform | 2025-06-18 | โ | โ |
TD Cowen | Downgraded | Outperform โ Market Perform | 2024-03-15 | โ | โ |
Jefferies | Downgraded | Buy โ Hold | 2024-03-15 | $3.00 | โ27.40% |
Guggenheim | Downgraded | Buy โ Neutral | 2024-03-14 | โ | โ |
Morgan Stanley | Reiterated | Equal Weight | 2023-08-04 | โ | โ |
Piper Sandler | Reiterated | Overweight | 2022-01-07 | $12.00 | +190.60% |
Cowen & Co. | Reiterated | Outperform | 2021-08-24 | โ | โ |
Institution
Needham
Reiterated ยท Buy ยท 2026-07-20
โ
โ
Chardan Capital
Reiterated ยท Buy ยท 2026-05-19
โ
โ
HC Wainwright & Co.
Reiterated ยท Buy ยท 2025-09-30
โ
โ
Oppenheimer
Reiterated ยท Outperform ยท 2025-09-25
$30.00
+626.40%
Mizuho
Reiterated ยท Outperform ยท 2025-06-18
โ
โ
TD Cowen
Downgraded ยท Outperform โ Market Perform ยท 2024-03-15
โ
โ
Jefferies
Downgraded ยท Buy โ Hold ยท 2024-03-15
$3.00
โ27.40%
Guggenheim
Downgraded ยท Buy โ Neutral ยท 2024-03-14
โ
โ
Morgan Stanley
Reiterated ยท Equal Weight ยท 2023-08-04
โ
โ
Piper Sandler
Reiterated ยท Overweight ยท 2022-01-07
$12.00
+190.60%
Cowen & Co.
Reiterated ยท Outperform ยท 2021-08-24
โ
โ
One row per institution ยท price target from the firm's latest published target